Your browser doesn't support javascript.
loading
Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 29-32, 2015.
Article in Chinese | WPRIM | ID: wpr-248414
ABSTRACT
<p><b>OBJECTIVE</b>To explore the correlation between UGT1A1 (*28, *60 and * 93) polymorphism and the adverse reactions in small cell lung cancer patients after irinotecan chemotherapy.</p><p><b>METHODS</b>Clinical data of 58 small cell lung cancer patients in extensive stage treated in our hospital were retrospectively analyzed. Polymerase chain reaction was used to amplify the UTG, and direct sequencing was performed to determine the UGT polymorphism. The adverse reactions ≥ grade 3 after irinotecan chemotherapy in patients with different UGT genotype were analyzed.</p><p><b>RESULTS</b>Amongthe 58 patients with extensive stage small cell lung cancer, there were 45 (77.6%) cases of wild type UGT1A1*28, 40 (69.0%) cases of wild type UGT1A1* 93, 38 (65.5%) cases of wild type UGT1A1*60, 18 cases of mutation in UGT1A1* 93 and 20 cases of mutation in UGT1A1*60. In UGT1A1 promoter position 28, there were 8 (13.8%) cases of TA5 mutation and 5 (8.6%) cases of TA7 mutation. Among the patients with TA5 mutation, 5 cases had ≥ grade 3 diarrhea, 3 cases had ≥ grade 3 leucopenia and 3 cases had ≥ grade 3 neutropenia, while among the patients with UGT1A1 * 93 mutation, 7 cases had ≥ grade 3 diarrhea, 6 cases had ≥ grade 3 leucopenia and 4 cases had ≥ grade 3 neutropenia.</p><p><b>CONCLUSIONS</b>TA5 and UGT1A1* 93 mutation increase the risk of diarrhea and ≥ grade 3 leukopenia and neutropenia, however, wild type UGT1A1 (*28, * 93, *60) and mutant UGT1A1*60 do not increase those risks. Further prospective study in a larger number of patients is needed to clarify the association between UGT1A1*28, UGT1A1* 93 and UGT1A1*60 polymorphism and adverse reactions of irinotecan, and to help clinicians in choosing a better therapeutic modality for personalized chemotherapy to improve curative effect and reduce adverse reactions.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Polymorphism, Genetic / Camptothecin / Prospective Studies / Retrospective Studies / Promoter Regions, Genetic / Glucuronosyltransferase / Diarrhea / Drug Therapy / Small Cell Lung Carcinoma / Genetics Type of study: Observational study / Risk factors Limits: Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2015 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Polymorphism, Genetic / Camptothecin / Prospective Studies / Retrospective Studies / Promoter Regions, Genetic / Glucuronosyltransferase / Diarrhea / Drug Therapy / Small Cell Lung Carcinoma / Genetics Type of study: Observational study / Risk factors Limits: Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2015 Type: Article